Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2018

View Archived Issues

Autoantibodies contribute to memory dysfunction

Early diagnosis of gestational diabetes

Release of safety and efficacy data of pinometostat for the treatment of acute advanced leukemia

Preclinical identification of a potential druggable target for chronic kidney disease

Dissemination of data from four phase I studies GSK-2838232, a second-generation drug for HIV

Sunitinib noninferior to nephrectomy in patients with metastatic renal-cell carcinoma

Potential new anti-obesity target identified

GT Biopharma initiates OXS-1550 combination study with a multi billion dollar oncology drug

Biogen describes new mitogen-activated protein kinase kinase kinase 5 inhibitors

TGF-beta decoy receptors patented by Tessa Therapeutics

Inovelon receives marketing authorisation extension in Europe

Updated data presented from long-term extension phase Ib study of aducanumab

First patient dosed in phase III study of ZL-2306 in SCLC

Positive topline data presented from phase Ib study of TAR-302 in idiopathic overactive bladder

AZD-5718: an oral FLAP inhibitor for the treatment of CAD

Development of a new PAM for the treatment of Parkinson's disease

Gradalis initiates phase III study of Vigil in Ewing's sarcoma

Clinical trials completed for Celltrion's Remsima SC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...